DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

Castle Biosciences celebrates an incredible milestone — the 200,000th order of the DecisionDx-Melanoma test! This milestone is so much more than a number: it represents 200,000 opportunities to provide clinicians and their patients with more accurate, more personalized insights that help guide their treatment plan decisions in melanoma care. With every test, we're empowering health care professionals to make more informed and more precise decisions that can fundamentally transform lives.Castle founder, pres ...